Widthness LLC

Advanced Business and Technology – Intel® Xeon® and A.I. Powered

New blood cancer therapy successful in three-quarters of trial patients

1 min read
New blood cancer therapy successful in three-quarters of trial patients

Image caption: The new treatment is currently under application for review by the FDA. Depositphotos. Article by Rich Haridy. New Atlas – December 11, 2022.

New data from an ongoing Phase 1/2 clinical trial has revealed an experimental immunotherapy led to successful response rates in 73% of patients suffering from multiple myeloma, a deadly form of blood cancer. Based on this promising data, an application to the US Food and Drug Administration (FDA) has been filed to bring the drug to market. […]

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.